Literature DB >> 7769992

Full-length cDNA cloning and distribution of human dopamine D4 receptor.

M Matsumoto1, K Hidaka, S Tada, Y Tasaki, T Yamaguchi.   

Abstract

Dopamine D4 receptor is the focus of interest in terms of pharmacological profile and possible relation to the disease. Using poly A+RNA from human retina as a template, we succeeded in cloning of full-length cDNA of the human dopamine D4 receptor by improved reverse transcription-polymerase chain reaction (RT-PCR). From the RT-PCR products, two polymorphic variants which had two and four tandem repeats in the putative third cytoplasmic loop were obtained. Transient expression of the full-length cDNA in COS-1 cells produced [3H]spiperone binding sites with a high affinity. These results confirmed the existence of the D4 receptor mRNA containing a different number of polymorphic tandem repeats in native human tissues. The RT-PCR method demonstrated the restricted distribution of the D4 mRNA in human tissues and brain regions. The mRNA was detected at the highest level in the retina, followed by the brain, placenta, and kidney. Among brain regions, relatively low levels for mRNA of the human D4 receptor were observed in the nigrostriatal pathway compared with the mesolimbic system. The distribution of the mRNA in human brain suggests that the D4 receptor plays a different role in the central nervous system compared with the D2 receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769992     DOI: 10.1016/0169-328x(94)00245-a

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  25 in total

1.  D4 dopamine and metabotropic glutamate receptors in cerebral cortex and striatum in rat brain.

Authors:  M A Berger; M C Defagot; M J Villar; M C Antonelli
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

2.  Autoradiographic localization of the putative D4 dopamine receptor in rat brain.

Authors:  M C Defagot; M C Antonelli
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

Review 3.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

Review 4.  The importance of dopamine D4 receptors in the action and development of antipsychotic agents.

Authors:  G P Reynolds
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  A pharmacophore model for dopamine D4 receptor antagonists.

Authors:  J Boström; K Gundertofte; T Liljeforsa
Journal:  J Comput Aided Mol Des       Date:  2000-11       Impact factor: 3.686

6.  Pharmacological modifications in dopaminergic neurotransmission affect the quinpirole-evoked suppression of serotonin N-acetyltransferase activity in chick retina: an impact on dopamine D4-like receptors.

Authors:  J B Zawilska; T Derbiszewska; J Z Nowak
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia.

Authors:  Frank Boeckler; Holger Russig; Weining Zhang; Stefan Löber; John Schetz; Harald Hübner; Boris Ferger; Peter Gmeiner; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 8.  Dopamine, kidney, and hypertension: studies in dopamine receptor knockout mice.

Authors:  Xiaoyan Wang; Van Anthony M Villar; Ines Armando; Gilbert M Eisner; Robin A Felder; Pedro A Jose
Journal:  Pediatr Nephrol       Date:  2008-07-10       Impact factor: 3.714

9.  Corticosterone down-regulates dopamine D4 receptor in a mouse cerebral cortex neuronal cell line.

Authors:  Virginia G Barros; Lorena A Boado; Ana M Adamo; Raúl Caviedes; Pablo Caviedes; Marta C Antonelli
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 10.  The role of prolactin in andrology: what is new?

Authors:  Giulia Rastrelli; Giovanni Corona; Mario Maggi
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.